Article Text

Download PDFPDF
Randomised controlled trial
Weekly adalimumab significantly reduces the number of abscesses and inflammatory nodules in patients with moderate to severe hidradenitis suppurativa
  1. Jan Mekkes
  1. Correspondence to : Dr Jan Mekkes, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; j.r.mekkes{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrl.


Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease, characterised by the presence of inflamed nodules, abscesses, pustules, fistulas and scar tissue, usually located in the axillary and inguinal area. Treatment is difficult; most patients require a combination of surgical treatment and medical treatment. The clinical symptoms can be reduced considerably by using anti-inflammatory medication. Since 2001, several monoclonal antibodies have been tried in HS, including the tumour necrosis factor α (TNF-α) inhibitors infliximab, etanercept …

View Full Text


  • Competing interests None declared.

  • Ethics approval Local Ethical Committees.

  • Provenance and peer review Commissioned; internally peer reviewed.